After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company.
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines for Europe at Sandoz.
Novartis said this morning that it remains on course to make a decision on the future of its generics business Sandoz by the end of the year, amid signs of a "return towards normal business
German injectable medicines specialist Fresenius Kabi has made a pair of deals to kickstart its new strategic direction, including a majority stake in mAbxience that bolsters its position i